Citi analyst Geoff Meacham maintained a Hold rating on Pfizer (PFE – Research Report) today. The company’s shares closed yesterday at $26.80. Discover outperforming stocks and invest smarter ...

NEW YORK, Jan 14 (Reuters) - Pfizer (PFE.N), opens new tab on Tuesday appealed a federal judge's refusal to award the drugmaker $75.2 million from a more than decade-old insider trading settlement ...

NEW YORK (Reuters) - Pfizer on Tuesday appealed a federal judge's refusal to award the drugmaker $75.2 million from a more than decade-old insider trading settlement involving billionaire Steven A.

Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $32.00. The company’s shares closed today at $26.41. Discover ...

Pfizer stock (NYSE: PFE) lost about 5% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli ...

NEW YORK (Reuters) - Pfizer on Tuesday appealed a federal judge's refusal to award the drugmaker $75.2 million from a more than decade-old insider trading settlement involving billionaire Steven A.

Pfizer in a statement said Do No Harm's claims were without merit and that it was "proud of its commitment to diversity, equity, and inclusion." Virginia-based Do No Harm, which is a non-profit ...

(Reuters) -A U.S. appeals court on Friday revived a lawsuit by a conservative group opposed to diversity initiatives in medicine that challenged a Pfizer fellowship program designed to boost the ...

Pfizer's stock has underperformed, but management's focus on R&D and cost efficiencies should boost margins and free cash flow, supporting a Buy rating. Despite political headwinds, PFE's ...